NZ600984A - Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof - Google Patents

Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof

Info

Publication number
NZ600984A
NZ600984A NZ600984A NZ60098411A NZ600984A NZ 600984 A NZ600984 A NZ 600984A NZ 600984 A NZ600984 A NZ 600984A NZ 60098411 A NZ60098411 A NZ 60098411A NZ 600984 A NZ600984 A NZ 600984A
Authority
NZ
New Zealand
Prior art keywords
acetate
peaks
cyclopropylnaphthalen
ylthio
bromo
Prior art date
Application number
NZ600984A
Other languages
English (en)
Inventor
Irina Zamansky
Gabriel Galvin
Jean-Luc Girardet
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of NZ600984A publication Critical patent/NZ600984A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ600984A 2010-01-08 2011-01-05 Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof NZ600984A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29360210P 2010-01-08 2010-01-08
PCT/US2011/020233 WO2011085009A2 (en) 2010-01-08 2011-01-05 Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof

Publications (1)

Publication Number Publication Date
NZ600984A true NZ600984A (en) 2013-10-25

Family

ID=44306123

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600984A NZ600984A (en) 2010-01-08 2011-01-05 Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof

Country Status (20)

Country Link
US (2) US8524754B2 (enExample)
EP (1) EP2521716B1 (enExample)
JP (1) JP5696346B2 (enExample)
KR (1) KR20120104627A (enExample)
CN (1) CN102741234B (enExample)
AU (1) AU2011203708B2 (enExample)
BR (1) BR112012016795A2 (enExample)
CA (1) CA2785200C (enExample)
CL (1) CL2012001841A1 (enExample)
CO (1) CO6561780A2 (enExample)
EA (1) EA020183B1 (enExample)
ES (1) ES2563207T3 (enExample)
MX (1) MX2012007925A (enExample)
MY (1) MY161482A (enExample)
NZ (1) NZ600984A (enExample)
PH (1) PH12012501391A1 (enExample)
SG (1) SG182404A1 (enExample)
TW (1) TWI451867B (enExample)
WO (1) WO2011085009A2 (enExample)
ZA (1) ZA201204938B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560642A4 (en) * 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
MY172534A (en) * 2010-12-30 2019-11-29 Ardea Biosciences Inc Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
ES2704233T3 (es) 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103588716A (zh) * 2013-11-22 2014-02-19 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的新晶型及其制备方法
CA2931430A1 (en) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
WO2015095703A1 (en) 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
CN105315218A (zh) * 2014-07-17 2016-02-10 天津药物研究院 一种制备lesinurad中间体1-萘基三唑硫酮的方法
CN105622427A (zh) * 2014-10-31 2016-06-01 天津药物研究院有限公司 一种制备lesinurad中间体4-环丙基-1-萘胺的方法
CN105820130B (zh) * 2015-01-08 2018-06-22 天津药物研究院有限公司 三氮唑正丙酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
CN105985296B (zh) * 2015-02-13 2018-10-16 天津药物研究院有限公司 一种可以工业化的lesinurad中间体1-萘基三唑硫酮的精制工艺
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
CN104817509B (zh) * 2015-04-13 2019-05-17 安徽省逸欣铭医药科技有限公司 Lesinurad类似物及其制备方法和医药用途
CN106187926B (zh) * 2015-04-30 2018-11-27 天津药物研究院有限公司 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (zh) * 2016-03-01 2018-05-18 山东大学 一种治疗痛风的三唑巯乙酸类化合物的制备方法
CN107337649B (zh) * 2016-04-29 2020-10-16 四川科伦药物研究院有限公司 一种乙酸钠水合物无定型及其制备方法和用途
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
WO2018085932A1 (en) 2016-11-10 2018-05-17 Apotex Inc. Novel crystalline forms of lesinurad
CN106632108A (zh) * 2016-12-14 2017-05-10 湖南欧亚生物有限公司 一种来司诺雷的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ME01512B (me) 2004-08-25 2014-04-20 Ardea Biosciences Inc S-triazolil alfa-merkaptoacetanilida kao inhibitori HIV reversne transkriptaze
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
CN102186832B (zh) * 2008-09-04 2014-04-02 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
MY172534A (en) 2010-12-30 2019-11-29 Ardea Biosciences Inc Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof

Also Published As

Publication number Publication date
HK1172622A1 (zh) 2013-04-26
EA201270676A1 (ru) 2013-01-30
EP2521716A4 (en) 2013-07-10
CO6561780A2 (es) 2012-11-15
EP2521716B1 (en) 2015-12-30
PH12012501391A1 (en) 2012-10-29
JP5696346B2 (ja) 2015-04-08
EA020183B1 (ru) 2014-09-30
JP2013516473A (ja) 2013-05-13
US8524754B2 (en) 2013-09-03
SG182404A1 (en) 2012-08-30
WO2011085009A2 (en) 2011-07-14
AU2011203708B2 (en) 2013-08-01
US20120129903A1 (en) 2012-05-24
CN102741234B (zh) 2015-11-25
MX2012007925A (es) 2012-08-03
CA2785200A1 (en) 2011-07-14
MY161482A (en) 2017-04-14
ZA201204938B (en) 2014-12-23
CL2012001841A1 (es) 2013-08-23
TWI451867B (zh) 2014-09-11
KR20120104627A (ko) 2012-09-21
WO2011085009A3 (en) 2011-11-10
CA2785200C (en) 2015-02-24
BR112012016795A2 (pt) 2020-09-01
ES2563207T3 (es) 2016-03-11
AU2011203708A1 (en) 2012-07-26
TW201143767A (en) 2011-12-16
CN102741234A (zh) 2012-10-17
EP2521716A2 (en) 2012-11-14
US20130345271A1 (en) 2013-12-26

Similar Documents

Publication Publication Date Title
NZ610104A (en) Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
MY161482A (en) Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
JP2013516473A5 (enExample)
WO2010141600A3 (en) Improved method for synthesizing pirfenidone
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
WO2014008295A8 (en) Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
WO2011024192A3 (en) Novel polymorphs of raltegravir
WO2014041559A3 (en) Process for preparation of dabigatran etexilate and intermediates thereof
WO2011002407A1 (en) Novel compounds for treatment of neurodegeneration associated with diseases, such as alzheimer's disease or dementia
JPWO2016017826A1 (ja) キサンチンオキシダーゼ阻害薬
NZ591870A (en) Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
WO2009037538A3 (en) Process for the preparation of lamivudine form i
CA2794389A1 (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
WO2009021943A3 (de) Neues herstellverfahren
EP3109241A1 (en) Method of refining valsartan comprising more than 10% d-isomers
WO2017125941A1 (en) An improved process for the preparation of regorafenib
WO2010100512A8 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US20170334926A1 (en) Process for preparing substituted indole compounds
WO2009027811A3 (en) Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same
WO2010086700A3 (en) An improved process for the preparation of choline salt of fenofibric acid and its novel polymorph
KR101523264B1 (ko) 올메사탄 메독소밀의 유연물질의 제조방법
WO2009072139A8 (en) Process for producing 2-[1-methyl-5-(4-methylbenzoyl)- pyrrol-2- yl]acetic acid or salt thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2016 BY CPA GLOBAL

Effective date: 20141219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2017 BY COMPUTER PACKAGES INC

Effective date: 20151218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2018 BY COMPUTER PACKAGES INC

Effective date: 20161231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2019 BY COMPUTER PACKAGES INC

Effective date: 20171219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2020 BY CPA GLOBAL

Effective date: 20181129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2021 BY CPA GLOBAL

Effective date: 20191205

LAPS Patent lapsed